Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftazidime–tazobactam vs cefoperazone–sulbactam in acute respiratory or urinary tract bacterial infections
CTR20130999Phase 2Active
- Sponsor
- Xiangbei Welman Pharmaceuticals
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ceftazidime + tazobactam in acute bacterial respiratory infection (ABRI), Acute Bacterial Urinary Tract Infection (UTI), sponsored by Xiangbei Welman Pharmaceuticals. Started Mar 2014; status: active.
02
Drugs
ceftazidime + tazobactam
03
Conditions
acute bacterial respiratory infection (ABRI)Acute Bacterial Urinary Tract Infection (UTI)
Beyond the preview
Go deeper on CTR20130999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130999.